The interesting chart of torrent pharma caught my eye…
Wyckoff re-acumulation seems to be underway…
The fundamentals need a serious look…
Some updates-
TRP filed 13 ANDAs in FY18 [us market],currently 46 ANDAs are pending for approval including six from Biopharma.,Overall it has 51 filings pending with US FDA including 5 tentative approvals,plans to file 15-20 ANDAs in the US in FY19 and expects eight to 10 approvals. Launched Hydrocodonsuppository from Biopharma portfolio in 4QFY18, To launch 8-9 products in FY19, Spent Rs 4.6bn in R&D in FY18, Unichem domestic portfolio has started growing post acquisition, Brazil was flat due to higher base and disturbances, single digit [5-6%]growth in Brazil in FY19 expected, To see strong growth in Germany in FY19,launched 17 products in Germany in FY18 and plans to launch 16 more in FY19, Expect 27% effective tax rate in FY19, Capex guidance at Rs 2bn for FY19 (maintenance capex mainly, believes most of the fresh capex has been done in FY18).
The chronic: acute ratio for the domestic formulations is 3:1…
Management expects significant synergies from the acquisition and have guided for the Unichem portfolio to exceed market growth rate in the near to medium term.
Disclaimer…definitely interested, learning the fundamental story here , no positions as yet